VANFLYTA

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Japan, Lithuania, United States

Active ingredients

The drug VANFLYTA contains one active pharmaceutical ingredient (API):

1 Quizartinib UNII WK7Q6ZIZ10 - QUIZARTINIB DIHYDROCHLORIDE

Quizartinib is an inhibitor of the receptor tyrosine kinase FLT3. Quizartinib and its major metabolite AC886 competitively bind to the adenosine triphosphate (ATP) binding pocket of FLT3 with high affinity. Quizartinib and AC886 inhibit FLT3 kinase activity, preventing autophosphorylation of the receptor, thereby inhibiting further downstream FLT3 receptor signalling and blocking FLT3-ITDdependent cell proliferation. Read about Quizartinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
VANFLYTA Film-coated tablet	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01EX11		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EX Other protein kinase inhibitors
Discover more medicines within L01EX11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3053135, 3053146, 3053157, 3053168, 3053179
Country: FR	Base de données publique des médicaments	Identifier(s): 61354095, 69293541
Country: IT	Agenzia del Farmaco	Identifier(s): 050967013, 050967025, 050967037, 050967049, 050967052
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291060F1021, 4291060F2028
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1098046, 1098047, 1098048, 1098049, 1098050
Country: US	FDA, National Drug Code	Identifier(s): 65597-504, 65597-511